Canada
['Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness', 'Puerto Rico', 'Canada', 'A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)', 65, 'clinical trial']